Canals Carmen, Muñiz-Díaz Eduardo, Martínez Clara, Martino Rodrigo, Moreno Imma, Ramos Adelaida, Arilla Marina, Boto Neus, Pastoret Concepción, Remacha Angel, Sierra Jorge, Madoz Pedro
Blood Bank, Hospital de Sant Pau, Barcelona, Spain.
Transfusion. 2004 Nov;44(11):1603-11. doi: 10.1111/j.1537-2995.2004.04106.x.
Most studies indicate that ABO incompatibility has no effect on the clinical outcome after allogeneic peripheral blood progenitor cell (PBPC) transplantation (allo-PBPCT). However, it carries additional risks of hemolytic reactions, delayed red blood cell (RBC) engraftment, and pure red cell aplasia (PRCA). Data on these events after reduced intensity conditioning (RIC) regimens are limited, but recent studies have suggested a higher transplant-related mortality (TRM) and morbidity in this setting.
We investigated the impact of ABO-matching on the outcome of 77 patients included in a prospective RIC allo-PBPCT protocol, focusing on engraftment, transfusion requirements, graft-versus-host disease, TRM, and survival.
There were 17 (22%) minor and 8 (10%) major ABO-incompatible transplants. No graft failures were observed. After major ABO-incompatible grafts, RBC engraftment was delayed, longer thrombocytopenia periods were documented, and transfusion requirements increased. A transient mild hemolysis occurred in 10 patients, 7 (41%) minor and 3 (37%) major ABO-mismatched. A PRCA was observed in a O+ patient with a pretransplant anti-Jka, grafted from an A + Jka+ donor. Graft-versus-host disease, disease progression, and TRM were not affected by ABO matching.
ABO incompatibility was not associated with clinically relevant hemolysis after the RIC protocol used and did not impair the clinical outcome. PRCA was only observed in one patient, with a non-ABO RBC allo-antibody.
大多数研究表明,ABO血型不相容对异基因外周血祖细胞移植(allo-PBPCT)后的临床结局没有影响。然而,它会带来溶血反应、红细胞(RBC)植入延迟和纯红细胞再生障碍(PRCA)等额外风险。关于减低强度预处理(RIC)方案后这些事件的数据有限,但最近的研究表明在这种情况下移植相关死亡率(TRM)和发病率更高。
我们调查了ABO血型匹配对纳入前瞻性RIC allo-PBPCT方案的77例患者结局的影响,重点关注植入、输血需求、移植物抗宿主病、TRM和生存率。
有17例(22%)为 minor ABO血型不相容移植,8例(10%)为major ABO血型不相容移植。未观察到移植失败。在major ABO血型不相容移植后,RBC植入延迟,记录到血小板减少期更长,输血需求增加。10例患者发生短暂轻度溶血,7例(41%)为minor ABO血型不匹配,3例(37%)为major ABO血型不匹配。在一名O+患者中观察到PRCA,该患者移植前有抗Jka抗体,供者为A + Jka+。移植物抗宿主病、疾病进展和TRM不受ABO血型匹配的影响。
在所使用的RIC方案后,ABO血型不相容与临床相关溶血无关,也不损害临床结局。仅在一名患者中观察到PRCA,该患者有非ABO RBC同种抗体。